Clinical effectiveness of ulinastation combined with Xuebijing for treating sepsis：a systematic review

Abstract:

Objective：To evaluate the clinical effectiveness of ulinastation combined with Xuebijing for treating sepsis. Method：The database such as Cochrane library，PubMed，CBM，CNKI，VIP and WanFang Data were searched to collect randomized controlled trials（RCTs），and the relevant references of included studies were also retrieved. Studies were screened，data were extracted，and the methodological quality was assessed by two reviewers independently. Meta-analysis was conducted by using RevMan 5.2 software. Results：A total of 15 studies involving 1 222 participants（experimental group：509，control group：713） were included. The results showed that compared with the group of routine therapies and group of single administration of either Ulinastatin or Xuebijing，experi－mental group of Ulinastatin combined with Xuebijing was superior in the following aspects with significant differences：morality：RR=0.45，95%CI=0.35 to 0.59，7d APACHEⅡ：MD=-4.91，95%CI=-6.83 to -2.98；duration of mechanical ventilation：MD=-7.33，95%CI=-10.16 to -4.51，the average length of ICU stay：MD=-8.63，95%CI=-11.50 to -5.76. Conclusion：According to the domestic evidence，ulinastatin combined with Xuebijing for treating sepsis is superior to both the routine therapies and the single administration of either Ulinastatin or Xuebijing. It provides a new and prospective therapeutic method for sepsis. However，this con－clusion has to be further verified by large scale and double blinded RCTs.